• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿米卡星脂质体吸入混悬液致药物性机化性肺炎 1 例

A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.

机构信息

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan; Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan.

出版信息

J Infect Chemother. 2023 Aug;29(8):806-808. doi: 10.1016/j.jiac.2023.04.013. Epub 2023 Apr 23.

DOI:10.1016/j.jiac.2023.04.013
PMID:37098378
Abstract

Inhaled liposomal antimicrobials are known to cause hypersensitivity pneumonitis. Amikacin liposome inhalation suspension (ALIS) is a promising novel antimicrobial agent against refractory Mycobacterium avium complex infections. The frequency of drug-induced lung injury caused by ALIS is relatively high. To date, no reports of ALIS-induced organizing pneumonia diagnosed by bronchoscopy are available. We report a case of a 74-year-old female patient presenting with non-tuberculous mycobacterial pulmonary disease (NTM-PD). She was treated with ALIS for refractory NTM-PD. Fifty-nine days after starting ALIS, the patient developed a cough, and her chest radiographs indicated deterioration. She was diagnosed with organizing pneumonia based on pathological findings of the lung tissues obtained by bronchoscopy. After switching from ALIS to amikacin infusion, her organizing pneumonia improved. It is difficult to distinguish between organizing pneumonia and an exacerbation of NTM-PD based on chest radiography alone. Therefore, it is essential to perform an active bronchoscopy for diagnosis.

摘要

已知吸入性脂质体抗生素可引起过敏性肺炎。阿米卡星脂质体吸入混悬液(ALIS)是一种有前途的新型抗耐药鸟分枝杆菌复合感染的抗菌药物。ALIS 引起的药物性肺损伤的频率相对较高。迄今为止,尚无经支气管镜诊断的 ALIS 引起的机化性肺炎的报道。我们报告了一例 74 岁女性患者,患有非结核分枝杆菌肺病(NTM-PD)。她因难治性 NTM-PD 接受了 ALIS 治疗。在开始使用 ALIS 后 59 天,患者出现咳嗽,胸部 X 线片显示病情恶化。根据支气管镜获取的肺部组织的病理发现,患者被诊断为机化性肺炎。从 ALIS 转换为阿米卡星输注后,她的机化性肺炎得到改善。仅凭胸部 X 线片很难区分机化性肺炎和 NTM-PD 的恶化。因此,进行积极的支气管镜检查以明确诊断非常重要。

相似文献

1
A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.阿米卡星脂质体吸入混悬液致药物性机化性肺炎 1 例
J Infect Chemother. 2023 Aug;29(8):806-808. doi: 10.1016/j.jiac.2023.04.013. Epub 2023 Apr 23.
2
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study.卷曲霉素脂质体吸入混悬液治疗复杂(CONVERT)引起的治疗抵抗性肺病。一项前瞻性、开放标签、随机研究。
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
3
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.起始治疗 6 个月后,卷曲霉素脂质体吸入混悬液治疗耐多药鸟分枝杆菌复合群肺病的疗效。
BMC Pulm Med. 2024 Sep 10;24(1):442. doi: 10.1186/s12890-024-03261-w.
4
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.阿米卡星脂质体吸入混悬液治疗难治性鸟分枝杆菌复合群肺病:培养转换的可持续性和耐久性及长期暴露的安全性。
Chest. 2021 Sep;160(3):831-842. doi: 10.1016/j.chest.2021.03.070. Epub 2021 Apr 19.
5
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.硫酸卷曲霉素脂质体吸入混悬液治疗鸟分枝杆菌复合体肺病的研究进展
Drugs. 2019 Apr;79(5):555-562. doi: 10.1007/s40265-019-01095-z.
6
Amikacin Liposome Inhalation Suspension for Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial.阿米卡星脂质体吸入混悬液治疗复杂肺部疾病:一项为期 12 个月的开放性标签扩展临床试验。
Ann Am Thorac Soc. 2021 Jul;18(7):1147-1157. doi: 10.1513/AnnalsATS.202008-925OC.
7
Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study.卷曲霉素脂质体吸入混悬液治疗鸟分枝杆菌复合体肺病:CONVERT 研究中日本患者的随机、3 期亚组分析。
Respir Investig. 2024 Mar;62(2):284-290. doi: 10.1016/j.resinv.2023.12.012. Epub 2024 Jan 25.
8
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease.治疗耐药非结核分枝杆菌肺病患者中硫酸卷曲霉素脂质体吸入混悬液的群体药代动力学评价。
Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):277-287. doi: 10.1007/s13318-020-00669-7. Epub 2021 Feb 17.
9
Liposomal Amikacin Inhalation Suspension-induced Pneumonitis.脂质体阿米卡星吸入混悬液诱发的肺炎
Intern Med. 2022 Aug 15;61(16):2547-2549. doi: 10.2169/internalmedicine.8796-21. Epub 2022 Feb 1.
10
The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.阿米卡星脂质体吸入混悬液(Arikayce)在治疗成人耐药非结核分枝杆菌肺病中的应用。
Drug Des Devel Ther. 2020 Jun 10;14:2287-2294. doi: 10.2147/DDDT.S146111. eCollection 2020.

引用本文的文献

1
Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections.用于治疗分枝杆菌感染的脂质体包封抗生素
Antibiotics (Basel). 2025 Jul 20;14(7):728. doi: 10.3390/antibiotics14070728.
2
Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.抗生素肺部给药:现状与未来展望
Pharmaceutics. 2025 Jan 15;17(1):111. doi: 10.3390/pharmaceutics17010111.
3
Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Complex Pulmonary Disease: A Case Report.
难治性复杂肺部疾病中与阿米卡星脂质体吸入混悬液相关的药物性间质性肺疾病的诊断与管理:一例报告
Infect Drug Resist. 2023 Oct 10;16:6629-6634. doi: 10.2147/IDR.S427544. eCollection 2023.